Get the Stockscreener App
27.25
6.22%
-2.33
Galecto Inc stock is traded at $27.25, with a volume of 8,200.
It is down -6.22% in the last 24 hours and down -4.61% over the past month.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
See More
Previous Close:
$29.58
Open:
$27.18
24h Volume:
8,200
Relative Volume:
0.01
Market Cap:
$43.98M
Revenue:
-
Net Income/Loss:
$-38.35M
P/E Ratio:
-18.79
EPS:
-1.45
Net Cash Flow:
$-36.91M
1W Performance:
+11.07%
1M Performance:
-4.61%
6M Performance:
+630.96%
1Y Performance:
+404.36%
1-Day Range:
$27.18
$28.23
1-Week Range:
$22.18
$32.00
52-Week Range:
$2.01
$38.33
Galecto Inc Stock (GLTO) Company Profile
Name
Galecto Inc
Sector
Industry
Phone
45-70-70-52-10
Address
75 STATE STREET, BOSTON
Compare GLTO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLTO
Galecto Inc
|
27.49 | 47.33M | 0 | -38.35M | -36.91M | -1.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.58 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.82 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
830.94 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
363.26 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
341.94 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Galecto Inc Stock (GLTO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Initiated | Leerink Partners | Outperform |
| Dec-01-25 | Initiated | Guggenheim | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Nov-23-20 | Initiated | BofA Securities | Buy |
| Nov-23-20 | Initiated | Credit Suisse | Outperform |
| Nov-23-20 | Initiated | SVB Leerink | Outperform |
View All
Galecto Inc Stock (GLTO) Latest News
Fund Flows: Should I set a stop loss on CNFR2025 Price Targets & Community Consensus Trade Signals - baoquankhu1.vn
Exit Recap: What is Dow Incs book value per sharePortfolio Value Summary & Technical Buy Zone Confirmations - baoquankhu1.vn
Is Galecto Inc. stock supported by innovation pipelineTechnical Breakout Signals & Maximize Gains Professionally - bollywoodhelpline.com
Galecto, Inc. (NASDAQ:GLTO) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Movement Recap: Is Galecto Incs ROIC above industry averageJuly 2025 Setups & Community Verified Watchlist Alerts - baoquankhu1.vn
Galecto (GLTO) Price Target Increased by 13.89% to 41.82 - Nasdaq
Investment Recap: Can Galecto Inc stock double in next 5 yearsEarnings Recap Report & Safe Entry Point Alerts - Bộ Nội Vụ
Galecto on track to submit IND for mutCALR antibody by mid-2026 - Investing.com Nigeria
Galecto on track to submit IND for mutCALR antibody by mid-2026 By Investing.com - Investing.com India
Galecto (GLTO) Sets Ambitious Clinical Milestones for 2026 - GuruFocus
Galecto Showcases New mutCALR MPN Pipeline at JPM - TipRanks
Galecto Highlights Key Strategic Priorities and Anticipated 2026 Milestones - The Manila Times
Galecto, Inc. Reports Strategic Shift and Financial Results - MSN
Galecto Completes Acquisition of Damora Therapeutics - MSN
Galecto (NASDAQ:GLTO) Upgraded at Leerink Partnrs - Defense World
What risks investors should watch in Galecto Inc. stock2025 Year in Review & Consistent Growth Equity Picks - ulpravda.ru
Is Galecto Inc. stock attractive for hedge fundsJuly 2025 Breakouts & Daily Price Action Insights - Улправда
Should I hold or sell Galecto Inc. stock in 2025July 2025 Patterns & High Conviction Investment Ideas - ulpravda.ru
Galecto (NASDAQ:GLTO) Now Covered by Leerink Partners - Defense World
Leerink Partners Initiates Coverage of Galecto (GLTO) with Outperform Recommendation - Nasdaq
Leerink Partners Initiates Coverage on GLTO with 'Outperform' Ra - GuruFocus
Leerink Partners initiates coverage on Galecto stock with Outperform rating By Investing.com - Investing.com Australia
Leerink Partners initiates coverage on Galecto stock with Outperform rating - Investing.com
Galecto strengthens its leadership after recent acquisition in the US - medwatch.com
Galecto appoints former Blueprint Medicines executives as COO and CMO - MSN
Galecto Appoints Sherwin Sattarzadeh as Chief Operating Officer - marketscreener.com
Galecto appoints new chief operating officer, enhances leadership - TipRanks
Galecto announces key additions to leadership team - marketscreener.com
Galecto appoints Sherwin Sattarzadeh as chief operating officer and issues warrant - Investing.com
Galecto, Inc. Appoints New Chief Operating Officer - TradingView — Track All Markets
Galecto Announces Key Additions to Leadership Team - The Manila Times
Galecto (GLTO) grants large warrant and hires new Chief Operating Officer - Stock Titan
Galecto, Inc. Appoints Sherwin Sattarzadeh as Chief Operating Officer and Becker Hewes as Chief Medical Officer, Effective January 5, 2026 - marketscreener.com
Comparing Galecto (NASDAQ:GLTO) and Avidity Biosciences (NASDAQ:RNA) - Defense World
Is the Market Bullish or Bearish on Galecto Inc? - Benzinga
Will Galecto Inc stock pay special dividends2025 Historical Comparison & Growth-Oriented Investment Plans - Bộ Nội Vụ
Galecto Files to Register 60.5 Million Shares for Secondary Offering - marketscreener.com
GLTO SEC FilingsGalecto Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Galecto (NASDAQ:GLTO) Shares Down 13.3%Time to Sell? - MarketBeat
Galecto (NASDAQ:GLTO) Shares Down 13.3% – Time to Sell? - Defense World
[EFFECT] Galecto, Inc. SEC Filing - Stock Titan
Ideas Watch: Should I hold or sell Galecto Inc stock in 2025 - Bộ Nội Vụ
Why Galecto Inc. stock could benefit from AI revolution2025 Market WrapUp & Free Expert Approved Momentum Trade Ideas - Улправда
Galecto (GLTO) Price Target Increased by 12.50% to 36.72 - Nasdaq
How Galecto Inc. stock performs after earningsQuarterly Profit Summary & Reliable Breakout Forecasts - Улправда
How rising interest rates impact Galecto Inc. stock2025 Winners & Losers & Reliable Trade Execution Plans - DonanımHaber
Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Galecto, Inc. announces inducement grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Galecto (NASDAQ:GLTO) Price Target Raised to $36.00 at Guggenheim - Defense World
Galecto Inc Stock (GLTO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.22%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):